In an interview with Redeye, CEO Hanna Sjöström, discusses the company’s latest capital raise of approximately SEK 20 million and its significance for the future. For the first time, the company has attracted institutional investors, Cicero Funds and Adrigo Funds, while existing major shareholders, including Anmiro AB, have continued to increase their holdings.
Watch the full interview where CEO Hanna Sjöström shares insights into what makes Neola Medical an attractive investment opportunity and how the capital will be utilized to finance the company’s clinical studies and the planned FDA application.
Watch the full interview here: Redeye Interview with CEO Hanna Sjöström